Systemic immune-inflammation index in predicting... : European Journal of Gastroenterology & Hepatology
ting the prognosis of gastric cancer patients. This study aims to investigate the predictive validity of SII of NCR in EGC patients. Methods We reviewed data from EGC patients who...
Conclusions: SII could be considered a simple and effective predictor of NCR of ESD in EGC patients.
Examining the Role of Histaminergic, Orexinergic, and Cannabinergic Systems in Redox Regulation in Gastric Adenocarcinoma
Source : https://www.eurekaselect.com/article/129649
Histaminergic, orexinergic, and cannabinoid systems play a role in both physiologic and oncogenic mechanisms in digestive tissues. These three systems are important mediators of tumor transformation, as they are associated...
Conclusions: Overall, the repercussion of ROS modulation through these three systems on tumor activity in gastric cancer depends on intracellular and/or nuclear signals associated with proliferation, metastasis, angiogenesis, and cell death. Here, we review the role of these modulatory systems and redox alterations in gastric cancer.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10642-7
Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor...
Conclusions: INTEGRATE II provides a platform to evaluate the clinical utility of regorafenib alone, as well as regorafenib in combination with nivolumab in the treatment of participants with AGOC who have failed two or more lines of treatment. The results of this study will hopefully improve the current standard of care in the treatment of...
The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36755269/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: This study thus proposes a candidate combination therapy of ABE and JQ1 to improve the therapeutic efficacy and worth further investigation in clinical trials for GC.
Gastric adenocarcinoma with high‑level microsatellite instability: A case report
Source : https://www.spandidos-publications.com/10.3892/mco.2023.2612
Gastric cancer (GC) ranks fifth on the list of the most common malignancies worldwide. In Peru, gastric neoplasms are considered the second leading cause of mortality among males. Among the...
Conclusions: The present study describes the case of a 75‑year‑old patient, who was admitted in the hospital with a history of upper gastrointestinal bleeding and recurrent hospital admission, due to severe anemia. The patient presented with pale skin, normal vital functions, slight swelling of the lower extremities, and abdominal distention...